Among long-term responders, first-line bevacizumab-based therapy is more effective in patients with HER2-negative metastatic breast cancer (MBC) who were not previously treated with taxanes, a recent Spanish study suggests.
Among long-term responders, first-line bevacizumab-based therapy is more effective in patients with HER2-negative metastatic breast cancer (MBC) who were not previously treated with taxanes, a recent Spanish study suggests. The study, LORENA, also found that maintenance hormonal therapy (MHT) provides additional therapeutic benefits by extending progression-free survival (PFS) and overall survival (OS). The study was published in OncoTargets and Therapy.
Researchers, led by Andres Redondo, MD, and colleagues, conducted an ambispective, observational study that consisted of both a retrospective and prospective phase. During the retrospective phase, patients with HER2-negative MBC who were treated with bevacizumab-based first-line therapy were included. During the prospective phase, patients with PFS of 12 or more months were treated according to routine clinical practice procedures. OS and OFS were estimated using the Kaplan-Meier method; univariate and multivariate analyses of prognostic factors were also performed. A total of 148 women were included in the study (median age, 50 years; range, 29-81 years), and mean duration of exposure to bevacizumab was 18 months.
The majority of patients experienced objective response (complete, 23%; partial, 57%). Median PFS was 22.7 months and median OS was 58.2 months. In multivariate analyses, patients receiving MHT had longer PFS (P=.002; hazard ratio [HR], 1.8) and OS (P=.009; HR, 2.0), while patients not previously treated with taxanes had longer OS (P <.001; HR, 3.3). No unexpected adverse events were observed.
Although first-line combination therapy with bevacizumab and chemotherapy has shown some efficacy in the treatment of patients with MBC in phase 3 clinical trials, it has failed to significantly improve OS. In addition, the use of bevacizumab in this indication is controversial because the FDA has proposed withdrawal of marketing approval for MBC after deciding there is not enough evidence that the drug is safe and effective for this one indication.
“Identification of factors that predict long-term response to bevacizumab would provide patients with a valuable therapeutic option,” the authors say, and the LORENA study was conducted to describe the clinical characteristics of patients with MBC who have experienced long-term response to bevacizumab.
“The results suggest that long-term responders are relatively young (50 years of age), more often premenopausal, have stage IV disease at diagnosis, and have [fewer than] 3 sites of metastases,” they conclude. “The benefit of bevacizumab may be greater in patients who have not received prior treatment with taxanes and in those who received MHT.”
In 2017 the FDA approved the first biosimilar bevacizumab, Mvasi.
Redondo disclosed serving as an advisor for, and received honoraria and research funding from Roche, as did other coauthors.
Reference
Redondo A, Vazquez MR, Manso L, et al. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study. Onco Targets Ther. 2018;11:5845-5852. Doi: 10.2147/OTT.S170303.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.